Antitumor Effects of Human Monoclonal Antibodies on Human Malignant Glioma Xenografts and Their Clinical Application

  • Katsushi Taomoto
  • Akihiro Ijichi
  • Satoshi Matsumoto
  • Hideaki Hagiwara


Human anaplastic gliomas still have a poor prognosis despite current aggressive therapies such as microsurgery, advanced radiation therapy, combined chemotherapy and/or immuno-therapy. It has been widely reported that a major limitation of these treatments is the lack of tumor specificity. Hybridoma technology has made it possible to generate large quantities of monoclonal antibodies (MAB) which are highly specific to human malignant tumors. Such tumor-associated MABs are potentially powerful tools in the diagnosis and treatment of human malignant tumors. A large number of monoclonal antibodies has been produced by hybridomas from mouse × mouse or mouse × human cells, and those antibodies were used in the diagnosis and the treatment of human cancers [1–3].


Antitumor Effect Malignant Glioma Human Glioma Human Monoclonal Antibody Athymic Nude Mouse 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bourdon MA, Coleman RE, Blasberg RG, et al. (1984) Monoclonal antibody localization in subcutaneous and intracranial human glioma xenografts: Paired-label and imaging analysis. Anticancer Res 4: 133–140PubMedGoogle Scholar
  2. 2.
    Carrel S, de Tribolet N, Mach J-P (1982) Expression of neuroectodermal antigens common to melanomas, gliomas and neuroblastomas. Acta Neuropathol (Berl) 57: 158–164CrossRefGoogle Scholar
  3. 3.
    Dillman RO, Awler DL, Sobal RE, et al. (1982) Murine monoclonal antibody therapy in two patients with chronic lymphocytic leukemia. Blood 59: 1036–1045PubMedGoogle Scholar
  4. 4.
    Glassy MC, Handley HH, Hagiwara H, et al. (1983) UC 729-6, a human lymphoblastoid B-cell line useful for generating antibody-secreting human-human hybridomas. Proc Natl Acad Sci USA 80: 6327–6331PubMedCrossRefGoogle Scholar
  5. 5.
    Hagiwara H, Sato HG (1983) Human x human hybridoma producing monoclonal antibody against autologous cervical carcinoma. Mol Biol Med 1: 245–252PubMedGoogle Scholar
  6. 6.
    Hagiwara H, Ohtake H, Yuasa H (1985) Proliferation and antibody production of human × human hybridoma in serum-free media. In: Murakami H, Yamane I, Barnes DW, et al. (eds) Growth and differentiation of cells in defined environment. Springer Heidelberg, pp 1–6Google Scholar
  7. 7.
    Hagiwara H, Aotsuka Y (1987) Cytotoxicity of mixed human monoclonal antibodies reacting to tumor antigens (in Japanese). Acta Paediatr Jpn 29: 552–556PubMedGoogle Scholar
  8. 8.
    Koprowski H, Steplewski Z, Herlyn D, et al. (1978) Study of antibodies against human melanoma produced by somatic cell hybrids. Proc Natl Acad Sci USA 75: 3405–3409PubMedCrossRefGoogle Scholar
  9. 9.
    Mach JP, Buchegger F, Fornai M, et al. (1981) Use of radiolabeled monoclonal anti-CEA antibodies for detection of the human carcinomas by external photoscanning and tomocintigraphy. Immunol Today 2: 239–249CrossRefGoogle Scholar
  10. 10.
    Behnke J, Mach J-P, Buchegger F, et al. (1988) In vivo localisation of radiolabeled monoclonal antibody in human gliomas. Br J Neurosurg 2: 193–197PubMedCrossRefGoogle Scholar
  11. 11.
    Blasberg RG, Nakagawa H, Bourdon MA, et al. (1987) Regional localization of a glioma-associated antigen defined by monoclonal antibody 81C6 in vivo: Kinetics and implication for diagnosis and therapy. Cancer Res 47: 4432–4443PubMedGoogle Scholar
  12. 12.
    Phillips J, Alderson T, Sikora K, et al. (1983) Localization of malignant glioma by a radiolabeled human monoclonal antibody. J Neurol Neurosurg Psychiatry 46: 388–392PubMedCrossRefGoogle Scholar
  13. 13.
    Bullard DE, Adams CJ, Coleman RE, et al. (1986) In vivo imaging of intracranial human glioma xenografts comparing specific with nonspecific radiolabeled monoclonal antibodies. J Neurosurg 64: 257–262PubMedCrossRefGoogle Scholar
  14. 14.
    Chiou RK, Vessella RL, Limas C, et al. (1988) Monoclonal antibody-targeted radiotherapy of renal cell carcinoma using a nude mouse mode. Cancer 61: 1766–1775PubMedCrossRefGoogle Scholar
  15. 15.
    Nowak TP (1987) Monoclonal antibodies: Prospects for specific immunotherapy for gliomas. Am J Oncol 10: 278–280CrossRefGoogle Scholar
  16. 16.
    Lee Y, Bullard DE, Wikstrand CJ, et al. (1987) Comparison of monoclonal antibody delivery to intracranial glioma xenografts by intravenous and intra-carotid administration. Cancer Res 47: 1941–1946PubMedGoogle Scholar
  17. 17.
    Aotsuka Y, Hagiwara H (1988) Identification of a malignant cell-associated antigen recognized by a human monoclonal antibody. Eur J Cancer Clin Oncol 24 (5): 829–838PubMedCrossRefGoogle Scholar
  18. 18.
    Bigner DD (1981) Biology of gliomas: Potential clinical implications of glioma, cellular heterogeneity. Neurosurgery 9: 320–326PubMedCrossRefGoogle Scholar
  19. 19.
    Lee Y, Bigner DD (1985) Aspects of immunobiology and immnotherapy and uses of monoclonal antibodies and biologic immune modifiers in human gliomas. Neurol Clin 3: 901–917PubMedGoogle Scholar
  20. 20.
    Herlyn D, Powe J, Alavi A, et al. (1983) Radioimmunodetection of human tumor xenografts by monoclonal antibodies. Cancer Res 43: 2731–2735PubMedGoogle Scholar

Copyright information

© Springer-Verlag Tokyo 1991

Authors and Affiliations

  • Katsushi Taomoto
    • 1
  • Akihiro Ijichi
    • 1
  • Satoshi Matsumoto
    • 2
  • Hideaki Hagiwara
    • 3
  1. 1.Department of NeurosurgeryHyogo Prefectural Medical Center for AdultsAkashi, 673Japan
  2. 2.Department of NeurosurgeryKobe University School of MedicineKobe, 650Japan
  3. 3.Department of NeurosurgeryHagiwara Institute of HealthHyogoJapan

Personalised recommendations